scholarly journals Pulmonary vascular distensibility with passive leg raise is comparable to exercise and predictive of clinical outcomes in pulmonary hypertension

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Callyn J. Kozitza ◽  
Naga Dharmavaram ◽  
Ran Tao ◽  
Diana M. Tabima ◽  
Naomi C. Chesler ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Clinical Outcomes ◽  
Passive Leg Raise

scholarly journals CORRELATION BETWEEN RIGHT HEART CATHETERIZATION PRESSURES AND CLINICAL OUTCOMES IN PULMONARY HYPERTENSION

CHEST Journal ◽  
2020 ◽  
Vol 158 (4) ◽  
pp. A1584
Author(s):  
Keerthi Yarlagadda ◽  
Selin Sendil ◽  
Sahar Tahir ◽  
Panupong Hansrivijit ◽  
Vinod Nookala ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Clinical Outcomes ◽  
Right Heart Catheterization ◽  
Heart Catheterization ◽  
Right Heart

scholarly journals Clinical Outcomes in Patients with Pulmonary Hypertension Undergoing Total Hip Arthroplasty

2014 ◽  
Vol 10 (2) ◽  
pp. 131-135 ◽  
Author(s):  
David Kim ◽  
Kethy Jules-Elysee ◽  
Lauren Turteltaub ◽  
Michael K. Urban ◽  
Jacques T. YaDeau ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Total Hip Arthroplasty ◽  
Clinical Outcomes ◽  
Hip Arthroplasty ◽  
Total Hip

Residual pulmonary hypertension is associated with clinical outcomes in patients with acute pulmonary thromboembolism

2019 ◽  
Vol 34 (11) ◽  
pp. 1866-1873
Author(s):  
Tatsuro Ibe ◽  
Hiroshi Wada ◽  
Kenichi Sakakura ◽  
Seiichiro Yoshimura ◽  
Miyuki Ito ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Clinical Outcomes ◽  
Pulmonary Thromboembolism ◽  
Acute Pulmonary Thromboembolism ◽  
Residual Pulmonary Hypertension

scholarly journals Longitudinal clinical outcomes in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Wim A. Wuyts ◽  
Caroline Dahlqvist ◽  
Hans Slabbynck ◽  
Marc Schlesser ◽  
Natacha Gusbin ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Pulmonary Function ◽  
Clinical Outcomes ◽  
Real World ◽  
Lung Transplant ◽  
World Population ◽  
Duration Of Treatment

Abstract Background The PROOF registry is an observational study initiated in October 2013 with the aim to monitor disease progression in a real-world population of patients with idiopathic pulmonary fibrosis (IPF). Here, we present longitudinal clinical outcomes from the PROOF registry. Methods Patients with IPF were enrolled across eight centers in Belgium and Luxembourg. For all patients, clinical outcomes data were collected, including mortality, lung transplant, acute exacerbations, and pulmonary hypertension. For patients treated with pirfenidone at any time during follow-up (2013–2017), for any duration of treatment (the pirfenidone-treated population): pirfenidone treatment patterns were collected; changes in pulmonary function (forced vital capacity [FVC] and carbon monoxide diffusing capacity [DLco]) were reviewed up to 24 months post-inclusion; and time-to-event analyses from the time of registry inclusion were performed. Results The PROOF registry enrolled a total of 277 patients. During follow-up, 23.1% of patients died, 5.1% received a lung transplant, 5.4% experienced an acute exacerbation, and 6.1% had comorbid pulmonary hypertension. In the pirfenidone-treated population (N = 233, 84.1%), 12.9% of patients had a temporary dose discontinuation and 31.8% had a temporary dose reduction; 4.3% of patients permanently discontinued pirfenidone due to an adverse drug reaction. Mean percent predicted FVC was 81.2% (standard deviation [SD] 19.0) at Month 0 and 78.3% (SD 25.0) at Month 24, and mean percent predicted DLco was 47.0% (SD 13.2) and 45.0% (SD 16.5), respectively. Rates of ≥ 10% absolute decline in percent predicted FVC and ≥ 15% absolute decline in percent predicted DLco over 24 months were 31.0% and 23.2%, respectively. Mean times from registry inclusion to categorical absolute decline in percent predicted FVC and percent predicted DLco were 20.1 (standard error [SE] 0.6) months and 23.4 (SE 0.5) months, respectively; mean time from registry inclusion to death was 31.0 (SE 0.9) months. Conclusions The PROOF registry is a source of European data characterizing longitudinal clinical outcomes of patients with IPF. Over 12 months of follow-up, pulmonary function remained largely stable in patients with IPF who received pirfenidone for any duration of treatment. Pulmonary function remained similar at 24 months of follow-up, although patient numbers were lower. Trial registration PROOF is registered with the relevant authorities in Belgium and Luxembourg, with registration to Comité National d’Éthique et de Recherche (CNER) N201309/03–12 September 2013 and a notification to Comité National de Protection des Données (CNDP) for Luxembourg.

Six-Minute Walk Test as a Predictor of Diagnosis, Disease Severity, and Clinical Outcomes in Scleroderma-Associated Pulmonary Hypertension: The DIBOSA Study

Lung ◽  
2017 ◽  
Vol 195 (5) ◽  
pp. 529-536 ◽  
Author(s):  
Abhishek Gadre ◽  
Christian Ghattas ◽  
Xiaozhen Han ◽  
Xiaofeng Wang ◽  
Omar Minai ◽  
...  
Keyword(s):  
Pulmonary Hypertension ◽  
Clinical Outcomes ◽  
Disease Severity ◽  
Walk Test ◽  
Six Minute Walk Test ◽  
Minute Walk
Sign in / Sign up

Export Citation Format

Share Document